Phase II Trial of Consolidation Docetaxel and Samarium-153 in Patients With Bone Metastases From Castration-Resistant Prostate Cancer

Fizazi, Karim; Beuzeboc, Philippe; Lumbroso, J.; Haddad, Vincent; Massard, Christophe; Gross‐Goupil, Marine; Palma, Mario Di; Escudier, Bernard; Théodore, Christine; Loriot, Yohann; Tournay, Elodie; Bouzy, J.; Laplanche, Agnès

doi:10.1200/jco.2008.18.9811

Cited by 155 publications

(68 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A significantly superior PSA response (p = 0.0235) and median survival time (30 versus 11 months; p = 0.008) were also observed in these patients who were treated with combination therapy [Ricci et al 2007]. Further promising data have also been reported with combinations of docetaxel and 153Sm EDTMP [Fizazi et al 2009]. Trials with other radionuclides are expected to demonstrate similar effects.…”

Section: Current Opinionsupporting

confidence: 49%

From palliative therapy to prolongation of survival: ²²³RaCl₂ in the treatment of bone metastases

Liepe

Shinto

2016

Ther Adv Med Oncol

View full text Add to dashboard Cite

Abstract:Patients with hormone-refractory prostate cancer often have multiple bone metastases. The resulting bone pain is associated with reduced life quality, increased cost of therapy and impairment of overall survival. Trials with bone-targeting β-emitters have mostly showed an effect on alleviation of bone pain along with prolongation in survival, documented in only a limited number of patients. A randomized phase III trial (ALSYMPCA) using the α-emitter 223 RaCl 2 (Xofigo®) showed for the first time, a longer overall survival of 3.6 months in treated patients as a sign of an antitumor effect. The time to first skeletal-related events was also significantly longer in the therapy group compared with placebo. Because of the short range of α-emitter, the bone marrow toxicity of radium therapy is low, and so this radionuclide could also be a candidate for combination with chemotherapy. The elimination of 223 RaCl 2 is mainly through the gastrointestinal tract and side effects are mainly in this area. The procedure is similar to treatment with other bone-seeking agents and consists of six administrations of 50 kBq/kg bodyweight Xofigo®, repeated every 4 weeks. At present Xofigo® is only approved for hormone-refractory prostate cancer.

show abstract

Section: Current Opinionsupporting

confidence: 49%

From palliative therapy to prolongation of survival: ²²³RaCl₂ in the treatment of bone metastases

Liepe

Shinto

2016

Ther Adv Med Oncol

View full text Add to dashboard Cite

show abstract

“…It represents a key concept in emerging markets like Tunisia. Numerous studies have focused on the relationship between earnings management and disclosure (Allayannis et al, 2009;Iatridis et al, 2009), while others have examined the relationship between information disclosure and stocks liquidity (Matoussi, Karaa, and Maghraoui 2004;Bhattacharya, Desai, and Venkataraman,2013;Fizazi et al 2009 ).…”

Section: Introductionmentioning

confidence: 99%

Earnings Management, Accruals and Stock Liquidity

Sayari¹,

Omri²

2017

JFBM

View full text Add to dashboard Cite

Accounting indicators published by firms remain a privileged source of information for the financial market. However, the margin of freedom granted by accounting rules allows managers to manipulate financial statements for discretionary ends, in order to mislead stakeholders on the firm's economic conditions. Our study aims at examining the Tunisian context and tries to determine the effect of earnings management on stocks liquidity. The relationship between liquidity and accruals was examined, using the modified earnings management measurement model of Jones (1995). Our sample consists of 299 observations of Tunisian companies listed on the stock exchange during the 2000-2012period. Using a panel data qualitative approach, the obtained results point to a positive relationship between discretionary accruals and Tunisian firms' stocks (as estimated by the two measurement models). This indicates that discretionary accruals allow Tunisian investors to optimally construct their stocks portfolios. The results also highlighted a negative and a significant impact of transaction size and volume on firms'ask-bid spread.

show abstract

“…A renewed interest was seen recently with two studies investigating the effectiveness of the combination of BSRs and docetaxel in patients with castration-resistant prostate carcinoma [95,96]. In one of these studies by Fizazi et al, patients achieving stabilization following four cycles of docetaxel and estamustine were further treated with combined docetaxel and Sm-153.…”

Section: Bone-seeking Radiopharmaceuticals and Chemotherapymentioning

confidence: 99%

Management of bone metastases: recent advances and current status

Dennis¹,

Vassiliou²,

Balboni³

et al. 2012

J Radiat Oncol

View full text Add to dashboard Cite

This narrative review summarizes new and existing local and systemic management strategies for bone metastases from the fields of radiation oncology, medical oncology and orthopaedic surgery. Local management strategies are organized according to different clinical scenarios, with complicated bone metastases defined as those with associated pathological fractures, soft tissue components or those compressing the spinal cord or cauda equina, and uncomplicated lesions defined as those without these adverse features. The distinction applies for both sclerotic and lytic lesions. Systemic strategies are organized according to classes of therapeutic agents.

show abstract

Phase II Trial of Consolidation Docetaxel and Samarium-153 in Patients With Bone Metastases From Castration-Resistant Prostate Cancer

Abstract: Combining docetaxel and samarium-153-EDTMP in patients with bone metastases from CRPC is well tolerated, and it yields major pain relief that persists long after treatment. Overall survival compares favorably with that expected in this population of patients, most of whom exhibit symptoms.

Cited by 155 publications

References 40 publications

From palliative therapy to prolongation of survival: ²²³RaCl₂ in the treatment of bone metastases

From palliative therapy to prolongation of survival: ²²³RaCl₂ in the treatment of bone metastases

Earnings Management, Accruals and Stock Liquidity

Management of bone metastases: recent advances and current status

Contact Info

Product

Resources

About

Phase II Trial of Consolidation Docetaxel and Samarium-153 in Patients With Bone Metastases From Castration-Resistant Prostate Cancer

Cited by 155 publications

References 40 publications

From palliative therapy to prolongation of survival: 223RaCl2 in the treatment of bone metastases

From palliative therapy to prolongation of survival: 223RaCl2 in the treatment of bone metastases

Earnings Management, Accruals and Stock Liquidity

Management of bone metastases: recent advances and current status

Contact Info

Product

Resources

About

From palliative therapy to prolongation of survival: ²²³RaCl₂ in the treatment of bone metastases

From palliative therapy to prolongation of survival: ²²³RaCl₂ in the treatment of bone metastases